Sean Lee

Justin Zelin

Leland Gershell

Trevor Allred

- **CASI Pharmaceuticals, Inc.** announced that its **Import Drug Registration License for FOLOTYN® in China expired on August 25, 2025**.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]** 
- The **Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) did not grant the company's renewal application** for the license.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]** 
- As a direct consequence, CASI Pharmaceuticals **will immediately cease the sale of FOLOTYN® in China**.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]** 
- The company may, however, **continue FOLOTYN® clinical trial activities in China**.  **[1962738_0001104659-25-084032_tm2524476d1_6k.htm:1]**

CASI Pharmaceuticals (CASI)